Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Merck
Fish and Richardson
Federal Trade Commission
QuintilesIMS
Cantor Fitzgerald
Daiichi Sankyo
Covington
Chinese Patent Office
Moodys

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021268

« Back to Dashboard

NDA 021268 describes TEVETEN HCT, which is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. Additional details are available on the TEVETEN HCT profile page.

The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
Summary for 021268
Tradename:TEVETEN HCT
Applicant:Abbvie
Ingredient:eprosartan mesylate; hydrochlorothiazide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021268
Ingredient-typeThiazides
Mechanism of ActionAngiotensin 2 Receptor Antagonists
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 021268
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268 NDA Physicians Total Care, Inc. 54868-5281 54868-5281-1 30 TABLET in 1 BOTTLE (54868-5281-1)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength600MG;12.5MG
Approval Date:Nov 1, 2001TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength600MG;25MG
Approval Date:Nov 1, 2001TE:RLD:No

Expired US Patents for NDA 021268

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Teva
Citi
US Department of Justice
Argus Health
Moodys
Julphar
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot